BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 12585566)

  • 21. Risperidone-induced hyperprolactinemia in adolescents: A case series.
    Madhusoodanan S; Moise D
    J Clin Psychiatry; 2006 Jul; 67(7):1110-3. PubMed ID: 16889455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alcohol Use Disorders Identification Test (AUDIT) scores are elevated in antipsychotic-induced hyperprolactinaemia.
    Lawford BR; Barnes M; Connor JP; Heslop K; Nyst P; Young RM
    J Psychopharmacol; 2012 Feb; 26(2):324-9. PubMed ID: 21262859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele.
    Young RM; Lawford BR; Barnes M; Burton SC; Ritchie T; Ward WK; Noble EP
    Br J Psychiatry; 2004 Aug; 185():147-51. PubMed ID: 15286066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects.
    Roke Y; van Harten PN; Boot AM; Buitelaar JK
    J Child Adolesc Psychopharmacol; 2009 Aug; 19(4):403-14. PubMed ID: 19702492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials.
    Kinon BJ; Gilmore JA; Liu H; Halbreich UM
    Psychoneuroendocrinology; 2003 Apr; 28 Suppl 2():69-82. PubMed ID: 12650682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol.
    Markianos M; Hatzimanolis J; Lykouras L
    Eur Arch Psychiatry Clin Neurosci; 2001 Jun; 251(3):141-6. PubMed ID: 11697576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.
    Peuskens J; Pani L; Detraux J; De Hert M
    CNS Drugs; 2014 May; 28(5):421-53. PubMed ID: 24677189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.
    Haddad PM; Wieck A
    Drugs; 2004; 64(20):2291-314. PubMed ID: 15456328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives.
    Byerly M; Suppes T; Tran QV; Baker RA
    J Clin Psychopharmacol; 2007 Dec; 27(6):639-61. PubMed ID: 18004132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prolactin serum levels in paranoid versus nonparanoid male schizophrenia patients treated with risperidone.
    Segal M; Avital A; Derevenski A; Berstein S; Sandbank S; Weizman A
    Int Clin Psychopharmacol; 2007 Jul; 22(4):192-6. PubMed ID: 17519641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elevation of prolactin levels by atypical antipsychotics.
    Turrone P; Kapur S; Seeman MV; Flint AJ
    Am J Psychiatry; 2002 Jan; 159(1):133-5. PubMed ID: 11772702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolactin and macroprolactin levels in psychiatric patients receiving atypical antipsychotics: A preliminary study.
    Park YM; Lee SH; Lee BH; Lee KY; Lee KS; Kang SG; Lee HY; Kim W
    Psychiatry Res; 2016 May; 239():184-9. PubMed ID: 27010188
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Significant elevations of prolactin levels in patients who shifted from conventional depot antipsychotics to long-acting risperidone.
    Lai YC; Chiou CC; Chen CH; Huang MC
    J Clin Psychopharmacol; 2007 Oct; 27(5):523-4. PubMed ID: 17873693
    [No Abstract]   [Full Text] [Related]  

  • 34. Prolactin awareness: an essential consideration for physical health in schizophrenia.
    Montejo AL
    Eur Neuropsychopharmacol; 2008 May; 18 Suppl 2():S108-14. PubMed ID: 18346598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics.
    Chen CK; Huang YS; Ree SC; Hsiao CC
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1495-9. PubMed ID: 20732372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone.
    Kinon BJ; Gilmore JA; Liu H; Halbreich UM
    Psychoneuroendocrinology; 2003 Apr; 28 Suppl 2():55-68. PubMed ID: 12650681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risperidone-induced prolactin elevations in premenopausal women with schizophrenia.
    Dickson RA; Dalby JT; Williams R; Edwards AL
    Am J Psychiatry; 1995 Jul; 152(7):1102-3. PubMed ID: 7540803
    [No Abstract]   [Full Text] [Related]  

  • 38. [Hyperprolactinemia in mentally ill patients].
    Carvalho MM; Góis C
    Acta Med Port; 2011; 24(6):1005-12. PubMed ID: 22713195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prolactin fluctuation over the course of a day during treatments with three atypical antipsychotics in schizophrenic patients.
    Yasui-Furukori N; Furukori H; Sugawara N; Tsuchimine S; Fujii A; Inoue Y; Kaneko S
    Hum Psychopharmacol; 2010 Apr; 25(3):236-42. PubMed ID: 20373475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antipsychotic induced hyperprolactinaemia: a series of illustrative case reports.
    Haddad PM; Hellewell JS; Wieck A
    J Psychopharmacol; 2001 Dec; 15(4):293-5. PubMed ID: 11769824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.